Acrivon Therapeutics Analyst Ratings
Acrivon Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/06/2023 | 65.29% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/18/2023 | 114.88% | JonesTrading | → $26 | Initiates Coverage On | → Buy |
| 08/11/2023 | 65.29% | HC Wainwright & Co. | $21 → $20 | Reiterates | Buy → Buy |
| 06/02/2023 | 106.61% | Oppenheimer | → $25 | Initiates Coverage On | → Outperform |
| 05/08/2023 | 106.61% | BMO Capital | → $25 | Initiates Coverage On | → Outperform |
| 05/02/2023 | 98.35% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 04/20/2023 | 98.35% | HC Wainwright & Co. | → $24 | Initiates Coverage On | → Buy |
| 12/12/2022 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 12/12/2022 | 40.5% | Jefferies | → $17 | Initiates Coverage On | → Buy |
| 12/12/2022 | 106.61% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/06/2023 | 65.29% | HC Wainwright公司 | →$20 | 重申 | 購買→購買 |
| 2023年08月18日 | 114.88% | Jones Trading | →$26 | 開始承保 | →購買 |
| 2023年08月11日 | 65.29% | HC Wainwright公司 | $21→$20 | 重申 | 購買→購買 |
| 06/02/2023 | 106.61% | 奧本海默 | →$25 | 開始承保 | →跑贏大盤 |
| 05/08/2023 | 106.61% | 蒙特利爾銀行資本 | →$25 | 開始承保 | →跑贏大盤 |
| 05/02/2023 | 98.35% | HC Wainwright公司 | →$24 | 重申 | →購買 |
| 04/20/2023 | 98.35% | HC Wainwright公司 | →$24 | 開始承保 | →購買 |
| 2022年12月12日 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 2022年12月12日 | 40.5% | 傑富瑞 | →$17 | 開始承保 | →購買 |
| 2022年12月12日 | 106.61% | 派珀·桑德勒 | →$25 | 開始承保 | →超重 |
What is the target price for Acrivon Therapeutics (ACRV)?
Acrivon Treeutics(ACRV)的目標價格是多少？
The latest price target for Acrivon Therapeutics (NASDAQ: ACRV) was reported by HC Wainwright & Co. on September 6, 2023. The analyst firm set a price target for $20.00 expecting ACRV to rise to within 12 months (a possible 65.29% upside). 10 analyst firms have reported ratings in the last year.
阿克瑞豐治療公司(納斯達克代碼：ACRV)的最新目標價是由HC Wainwright&Co.於2023年9月6日報道的。這家分析公司將目標價定為20.00美元，預計ACRV將在12個月內上漲至65.29%(可能上漲65.29%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Acrivon Therapeutics (ACRV)?
Acrivon Treeutics(ACRV)的最新分析師評級是什麼？
The latest analyst rating for Acrivon Therapeutics (NASDAQ: ACRV) was provided by HC Wainwright & Co., and Acrivon Therapeutics reiterated their buy rating.
納斯達克(代碼：ACRV)的最新分析師評級由HC Wainwright&Co.提供，阿裡馮治療公司重申其買入評級。
When is the next analyst rating going to be posted or updated for Acrivon Therapeutics (ACRV)?
Acrivon治療公司(ACRV)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acrivon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acrivon Therapeutics was filed on September 6, 2023 so you should expect the next rating to be made available sometime around September 6, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Acrivon Treeutics的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Acrivon治療公司的最後一次評級是在2023年9月6日提交的，所以你應該預計下一次評級將在2024年9月6日左右提供。
Is the Analyst Rating Acrivon Therapeutics (ACRV) correct?
分析師對Acrivon Treeutics(ACRV)的評級正確嗎？
While ratings are subjective and will change, the latest Acrivon Therapeutics (ACRV) rating was a reiterated with a price target of $0.00 to $20.00. The current price Acrivon Therapeutics (ACRV) is trading at is $12.10, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Acrivon治療(ACRV)評級被重申，目標價在0.00美元至20.00美元之間。阿裡馮治療公司(ACRV)目前的交易價格為12.10美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。